Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Influence of Molecular Abnormalities on Treatment Response of the Regimen of Venetoclax Plus Azacytidine Combined With Homoharringtonine Versus Venetoclax Plus Hypomethylating Agents (HMA) in Relapsed/Refractory Acute Myeloid Leukemia

NCT05456048 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT05456048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05456048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Influence of Molecular Abnormalities on Treatment Response of the Regimen of Venetoclax Plus Azacytidine Combined With Homoharringtonine Versus Venetoclax Plus Hypomethylating Agents (HMA) in Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Observational
Overall status
Completed
Start date
December 3, 2018
Completion date
May 31, 2022
Enrollment
231 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytogenetic abnormality, gene abnormality, refractory acute myeloid leukemia, relapsed acute myeloid leukemia